Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

July 31, 2003

Study Completion Date

July 31, 2003

Conditions
Crohn's Disease
Interventions
DRUG

natalizumab

Trial Locations (18)

11021

Long Island Clinical Research Associates, LLP, Great Neck

23455

Gastroenterology Consultants, Virginia Beach

24541

Internal Medicine Associates, Danville

27612

Wake Research Associates, Raleigh

27804

Boice-Willis Clinic, Rocky Mount

28801

Asheville Gastroenterology, Asheville

29203

Columbia Gastroenterology Associates, Columbia

30342

Atlanta Gastroenterology Associates, Atlanta

32223

Borland Groover Clinic, Jacksonville

32605

Digestive Disease Associates, Gainesville

38120

Gastroenterology Center of the MidSouth, Memphis

Memphis Gastroenterology Group, Memphis

40536

University of Kentucky Medical Center, Lexington

59701

Mercury Street Medical, Butte

78745

Austin Gastroenterology, Austin

98101

Virginia Mason Medical Center, Seattle

98405

Digestive Health Specialists, Tacoma

02114

Massachusetts General Hospital, Boston

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Biogen

INDUSTRY